Business Wire

BACARDI

21.10.2020 11:02:12 CEST | Business Wire | Press release

Share
Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle

Bacardi, the world’s largest family-owned spirits company, has made a giant leap forward in the fight against climate change and plastic pollution today, as it unveils plans to put the world’s most sustainable spirits bottle on shelf by 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005281/en/

The new 100% biodegradable bottle will replace 80 Million plastic bottles – 3,000 tons of plastic – currently produced by Bacardi across its portfolio of brands every year.

This revolutionary move by Bacardi is possible thanks to its close collaboration with Danimer Scientific, a leading developer and manufacturer of biodegradable products. Petroleum-based plastics used by Bacardi today will be replaced by Danimer Scientific’s Nodax™ PHA, a biopolymer which derives from the natural oils of plant seeds such as palm, canola and soy. While a regular plastic bottle takes over 400 years to decompose, the new spirits bottle made from Nodax™ PHA will biodegrade in a wide range of environments, including compost, soil, freshwater and sea water, and after 18 months disappear without leaving behind harmful microplastics.

BACARDÍ® rum will be the first spirit to appear in the new bottle, before the plant-based material is rolled out to replace single-use plastic across the entire Bacardi supply chain and the company’s 200 brands and labels including BOMBAY SAPPHIRE® gin, GREY GOOSE® vodka, PATRÓN® tequila, MARTINI® vermouth and DEWAR’S® Scotch whisky.

Ned Duggan, Senior Vice President, BACARDÍ rum, said: “Over our 158-year history, BACARDÍ has always believed in respecting the world’s natural resources and acting responsibly, from the sustainable sourcing of our sugarcane to the water and energy used to make our rum. We’re now excited to be pioneering this new biopolymer technology for the benefit of all Bacardi brands and the entire spirits industry.”

As well as the new 100% biopolymer spirits bottle, Bacardi is also creating a sustainably sourced paper bottle. By integrating the Nodax™ PHA polymer, this alternative solution will have equally strong environmental credentials while ensuring the quality and taste of the spirit inside a bottle made of paper is as exceptional as one made of glass.

Jean-Marc Lambert, Senior Vice President, Global Operations for Bacardi, said: “When we set ourselves the goal of being 100% plastic free by 2030, we knew that it would take ground-breaking advances in packaging design to make it achievable, and that’s exactly what’s happening through our partnership with Danimer.”

Thanks to the versatility of this innovative new material, the Bacardi Packaging Development team will also crack one of the beverage industry’s longest-standing plastic problems – the plastic lining of bottle closures. “It may sound small,” says Jean-Marc, “But add that up across every bottle produced globally and we’re talking many tons of plastic every day. Once we’ve fixed the problem, we’ll be open sourcing the solution for the entire industry to use. This isn’t about competitive advantage it’s about doing the right thing for the planet.”

Today’s announcement by Bacardi represents a major step towards the company achieving its goal of being 100% plastic-free in the next 10 years. As well as launching the new biopolymer bottle in 2023, the company has also committed to removing all its non-essential, single-use plastic, including all plastic gift box materials and plastic point-of-sale materials, in the next three years.

Nodax™ PHA was verified as a truly biodegradable alternative to petrochemical plastics by the University of Georgia (UGA) and the UGA New Materials Institute in a 2018 study. Danimer Scientific currently uses the material for a wide range of applications, including thermoformed trays, drinking straws, flexible and multi-layer film packaging, coatings, disposable cutlery, and more.

“Nodax™ PHA is one of the most promising eco-friendly materials in the world today because it delivers the biodegradability that consumers demand without losing the quality feel they receive from traditional plastic,” said Scott Tuten, Chief Marketing & Sustainability Officer at Danimer Scientific. “The material provides the best of both worlds, and we look forward to working with Bacardi and incorporating PHA into their iconic packaging.”

In 2016, Bacardi led the drinks industry by committing to eliminate all single-use plastic straws in its cocktails. And two years ago, it began a collaboration with the Lonely Whale Foundation to remove single-use plastic straws from bars and restaurants. Danimer Scientific’s use of Nodax™ PHA to create the world’s first completely biodegradable plastic drinking straw in 2018 has complemented these initiatives to help reduce the global impact of plastic waste.

Find out more about Bacardi’s sustainability commitments and its vision to become the most environmentally responsible global spirits company at https://www.bacardilimited.com/corporate-responsibility/ .

Always drink responsibly

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .

About Danimer Scientific

Danimer Scientific is a pioneer in creating more sustainable, more natural ways to make plastic products. Danimer Scientific’s Nodax™ PHA possesses seven TUV AUSTRIA certifications and statements of industrial and home compostability, is biodegradable in anaerobic, soil, fresh water and marine environments and is 100% bio-based. All of Danimer Scientific’s biopolymers, including its Nodax™ PHA, are FDA approved for food contact. For more information, visit www.DanimerScientific.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye